Becton Dickinson & (BDX) Stock
Global medical technology firm supplying devices and instruments. Here's the price, business snapshot, and what's worth knowing about Becton Dickinson & in August 2026.
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It’s Moving
BDX gains traction as investors react to a stronger quarter and an upgraded full-year outlook.
- BDX hit a fresh 52-week high after the company’s fiscal third-quarter update showed earnings and revenue ahead of expectations, reinforcing confidence in its post-restructuring execution.
- Management lifted full-year EPS guidance, signaling that the company’s new operating structure is delivering better margin performance and steadier commercial momentum than investors had anticipated.
- Recent follow-through has been helped by strategic and operational headlines, including the PREVENT trial progress and leadership changes in quality oversight, which support the long-term growth narrative.
BDX gains traction as investors react to a stronger quarter and an upgraded full-year outlook.
- BDX hit a fresh 52-week high after the company’s fiscal third-quarter update showed earnings and revenue ahead of expectations, reinforcing confidence in its post-restructuring execution.
- Management lifted full-year EPS guidance, signaling that the company’s new operating structure is delivering better margin performance and steadier commercial momentum than investors had anticipated.
- Recent follow-through has been helped by strategic and operational headlines, including the PREVENT trial progress and leadership changes in quality oversight, which support the long-term growth narrative.
Sixth Month Growth Performance
next-earnings-question
BDX’s next earnings date is expected to be November 5, 2026. The report should cover fiscal Q4 2026, based on the company’s historical quarterly reporting pattern. This timing is an estimate rather than a confirmed company announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton, Dickinson and Company's stock, expecting it to rise in value.
Financial Health
Becton, Dickinson and Company is showing strong revenue and profits, with solid cash generation capabilities.
Dividend
Becton, Dickinson and Company's dividend yield of 2.42% offers a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $41.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
